{
    "clinical_study": {
        "@rank": "31908", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Cornstarch, National Formulary"
            }, 
            {
                "arm_group_label": "Standard Dose Kappa Agonist", 
                "arm_group_type": "Experimental", 
                "description": "Pentazocine/Naloxone 50/0.5 mg"
            }, 
            {
                "arm_group_label": "Half Dose Kappa Agonist", 
                "arm_group_type": "Experimental", 
                "description": "Pentazocine/Naloxone 25/0.25 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "Studies suggest that kappa agonists (KA) and peripherally restricted kappa agonists (PRKAs)\n      may affect thermoregulation.  This pilot study has the aim to establish proof of concept\n      regarding efficacy of an oral kappa agonist (KA) for the treatment of menopausal hot\n      flashes."
        }, 
        "brief_title": "Effects of a Kappa Agonist on Hot Flashes in Menopausal Women", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Treatment of Menopausal Hot Flashes", 
        "condition_browse": {
            "mesh_term": "Hot Flashes"
        }, 
        "detailed_description": {
            "textblock": "To establish proof of concept regarding efficacy of an oral kappa agonist (KA), Pentazocine/\n      Naloxone 50/0.5 mg, for the treatment of menopausal hot flashes.\n\n      To gather data in support of a future proposal to study the safety and efficacy of a PRKA, a\n      type of KA, for amelioration of menopausal hot flashes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy women 45-60 years of age; 12 months amenorrhea\n\n          2. Documentation of > 8 moderate to severe, daily hot flashes during one week of\n             baseline monitoring using daily diaries\n\n          3. Availability of a family member or friend to drive participant home following clinic\n             visits\n\n        Exclusion Criteria:\n\n          1. Use of hormonal prescription medication or supplements for vasomotor symptoms (VMS)\n\n          2. Use of narcotics\n\n          3. Use of  SSRI (selective serotonin reuptake inhibitor)/SNRI (serotonin-norepinephrine\n             reuptake inhibitors), gabapentin, MAOI (monoamine oxidase inhibitor),\n             anti-epileptics, sedatives\n\n          4. History of polycystic ovarian syndrome or hirsutism\n\n          5. Current history of depression\n\n          6. Any chronic or acute medical illnesses including renal, hepatic, pulmonary diseases,\n             or seizures\n\n          7. Substance abuse\n\n          8. Severe corn allergy\n\n          9. Known allergic reaction to pentazocine or naloxone\n\n         10. Presence of a condition or abnormality that in the opinion of the Investigator would\n             compromise the safety of the patient or the quality of the data\n\n         11. Hysterectomy\n\n         12. Use of anticholinergic medications\n\n         13. Lactating or pregnant"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "11", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02070718", 
            "org_study_id": "43952-A", 
            "secondary_id": "GYN-01-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard Dose Kappa Agonist", 
                "intervention_name": "Standard Dose Kappa Agonist", 
                "intervention_type": "Drug", 
                "other_name": "Pentazocine/Naloxone 50/0.5 mg"
            }, 
            {
                "arm_group_label": "Half Dose Kappa Agonist", 
                "intervention_name": "Half Dose Kappa Agonist", 
                "intervention_type": "Drug", 
                "other_name": "Pentazocine/Naloxone 25/0.25 mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naloxone", 
                "Pentazocine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "hot flashes", 
            "menopause", 
            "kappa agonist"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98195"
                }, 
                "name": "University of Washington"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effects of a Kappa Agonist on Hot Flashes in Menopausal Women", 
        "other_outcome": [
            {
                "description": "Baseline (1st visit) single time point", 
                "measure": "Serum Follicle Stimulating Hormone", 
                "safety_issue": "No", 
                "time_frame": "Baseline only"
            }, 
            {
                "description": "Baseline (1st visit) single time point only.", 
                "measure": "Serum Estradiol", 
                "safety_issue": "No", 
                "time_frame": "Baseline only"
            }
        ], 
        "overall_official": {
            "affiliation": "University of Washington", 
            "last_name": "Susan D Reed, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Objectively measured hot flash frequency by changes in skin conductance over 8 hours on 3 separate study visits 3-14 days apart.", 
            "measure": "Hot Flashes", 
            "safety_issue": "No", 
            "time_frame": "1-4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02070718"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Washington", 
            "investigator_full_name": "Susan Reed", 
            "investigator_title": "Professor, Obstetrics & Gynecology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Self-reported diary documentation of time and occurence of hot flashes and intensity of hot flashes over 8 hours on 3 separate study visits 3-14 days apart.", 
                "measure": "Subjectively measured hot flashes", 
                "safety_issue": "No", 
                "time_frame": "1-4 weeks"
            }, 
            {
                "description": "Serum collected at each visit baseline (before administration of treatment) and at 20-minute intervals over 8 hours on 3 separate study visits 3-14 days apart.", 
                "measure": "Change in Serum Leutinizing Hormone", 
                "safety_issue": "No", 
                "time_frame": "1-4 weeks"
            }
        ], 
        "source": "University of Washington", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute on Aging (NIA)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Eunice Kennedy Shriver National Institute of Child Health and Development (NICHD)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Center for Complementary and Alternative Medicine (NCCAM)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Office of Research and Women's Health (ORWH)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Center for Advancing Translational Science (NCATS)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Washington", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}